The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with ...

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

A recent study published in Genes & Diseases reveals new insights into the relationship between immune cell characteristics, blood metabolites, and ...

FDA approves subcutaneous form of J&J and Genmab’s anti-CD38 drug Darzalex for the treatment of multiple myeloma, relieving pressure from Sanofi’s recently launched Sarclisa ...